Reuters logo
BRIEF-Nichi-Iko Pharmaceutical and unit says marketing approval for Infliximab BS for I.V. Infusion 100 mg "Nichi-Iko" and "AYUMI"
September 27, 2017 / 9:08 AM / 23 days ago

BRIEF-Nichi-Iko Pharmaceutical and unit says marketing approval for Infliximab BS for I.V. Infusion 100 mg "Nichi-Iko" and "AYUMI"

Sept 27 (Reuters) - Nichi-Iko Pharmaceutical Co Ltd

* Says it received marketing approval for Infliximab BS for I.V. Infusion 100 mg “Nichi-Iko” from the Ministry of Labour, Health, and Welfare on Sept. 27

* Says its unit, Yakuhan Pharmaceutical Co Ltd, received manufacturing and marketing approval for Infliximab BS for I.V. infusion 100 mg “AYUMI”

Source text in Japanese:goo.gl/UaMyff; goo.gl/ZutWme

Further company coverage: (Beijing Headline News)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below